Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Acts on Dietary Supplements Containing DMHA and PhenibutCFSAN Constituent Updates FDA Acts on Dietary Supplements Containing DMHA and Phenibut
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintConstituent Update

April 16, 2019

On April 10, 2019, the FDA issued 12 warning letters to companies whose dietary supplement products are in violation of the law.

The FDA issued 9 warning letters to companies whose products are marketed as dietary supplements and labeled to contain DMHA. DMHA has been found in numerous dietary supplement products, often marketed for sports performance and weight loss. The FDA has determined that DMHA is either a “new dietary ingredient” for which the FDA has not received the required New Dietary Ingredient notification or that it is an unsafe food additive. The FDA considers dietary supplements containing DMHA to be adulterated.

DMHA is also known as:

1,5-Dimethylhexylamine
	1,5-DMHA
	2-amino-5-methylheptane
	2-amino-6-methylheptane
	2-aminoisoheptane
	2-Heptylamine, 6-methyl-
	2-Isooctyl amine
	2-Metil-6-amino-eptano
	6-Amino-2-methylheptane
	Amidrine
	Octodrine
	VaporpacThe FDA also issued 3 warning letters to companies whose products are marketed as dietary supplements and labeled to contain phenibut. Phenibut has been found in products labeled as dietary supplements, sometimes marketed for uses such as a sleep aid. Phenibut does not meet the definition of a dietary ingredient Under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Products labeled as dietary supplements that list phenibut as a dietary ingredient are misbranded.

Phenibut is also known as:

fenibut
	phenigam
	PhGaba
	Phenigamma
	Phenygam
	4-Amino-3-phenylbutanoic acid
	β-(aminomethyl)benzenepropanoic acid
	beta-(Aminomethyl)hydrocinnamic acid
	β-phenyl-γ-aminobutyric acidThe companies have 15 business days from the date of receipt of the letter to communicate to the agency the specific steps they will take to bring their products into compliance with the law. The warning letters also caution the companies that the FDA may take enforcement action without further notice if they do not immediately cease distribution of the products.

A reaffirmed commitment to traditional advisory and enforcement actions, such as warning letters, in combination with the newly launched rapid-response tool, the Dietary Supplement Ingredient Advisory List, are integral parts of the FDA’s overall effort to strengthen the agency’s regulation and oversight of dietary supplements. We continue to look for ways to modernize our approach to protecting consumers from misbranded, unsafe, or otherwise unlawful dietary supplements.

Additional Information:

DMHA in Dietary Supplements
	Phenibut in Dietary Supplements
	Deputy Commissioner's StatementWarning Letters (DMHA):

Line One Nutrition
	Iron Brothers Supplements
	Eflow Nutrition LLC
	Hi-Tech Pharmaceuticals, Inc.
	IQ Formulations, LLC / DBA Metabolic Nutrition Inc.
	Down To Earth Solutions, LLC
	Forbidden Labz
	Total Body Nutrition Labs, LLC
	Goldstar Performance ProductsWarning Letters (Phenibut):

Atomixx
	Evol Nutrition Associates, Inc.
	NeusoScience

                                                                                  Content current as of:
      04/29/2019
              
              
Regulated Product(s)
		 Dietary SupplementsCFSAN Constituent Updates
 Subscribe to CFSAN Constituent Updates
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop